Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.

Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D.

http://www.ncbi.nlm.nih.gov/pubmed/21903413